Rezolute/$RZLT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Rezolute
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.
Ticker
$RZLT
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
68
ISIN
US76200L3096
Website
Rezolute Metrics
BasicAdvanced
$474M
-
-$1.11
1.04
-
Price and volume
Market cap
$474M
Beta
1.04
52-week high
$5.72
52-week low
$2.22
Average daily volume
1.2M
Financial strength
Current ratio
8.429
Quick ratio
8.254
Long term debt to equity
1.405
Total debt to equity
2.15
Profitability
EBITDA (TTM)
-77.116
Management effectiveness
Return on assets (TTM)
-52.85%
Return on equity (TTM)
-95.15%
Valuation
Price to book
4.06
Price to tangible book (TTM)
4.06
Price to free cash flow (TTM)
-5.53
Free cash flow yield (TTM)
-18.08%
Free cash flow per share (TTM)
-100.18%
Growth
Earnings per share change (TTM)
-1.83%
3-year earnings per share growth (CAGR)
-28.70%
10-year earnings per share growth (CAGR)
-27.24%
What the Analysts think about Rezolute
Analyst ratings (Buy, Hold, Sell) for Rezolute stock.
Bulls say / Bears say
Rezolute's lead candidate, ersodetug, has received Breakthrough Therapy Designation from the FDA for treating hypoglycemia due to tumor-induced hyperinsulinism, potentially expediting its development and approval process. (ir.rezolutebio.com)
The company successfully raised approximately $97 million in April 2025, extending its cash runway to mid-2027, which supports ongoing and future clinical trials. (ir.rezolutebio.com)
Rezolute is advancing two Phase 3 trials for ersodetug targeting different forms of hyperinsulinism, with topline results expected in the second half of 2025 and 2026, indicating a robust pipeline with significant market potential. (ir.rezolutebio.com)
Rezolute reported a net loss of $18.9 million for the third quarter of fiscal 2025, an increase from $17.1 million in the same period the previous year, reflecting rising operational expenses. (ir.rezolutebio.com)
The company's cash, cash equivalents, and investments decreased to $88.4 million as of March 31, 2025, down from $127.1 million as of June 30, 2024, indicating a significant cash burn rate. (ir.rezolutebio.com)
Despite advancing clinical programs, Rezolute has yet to generate revenue from product sales, relying heavily on external funding to sustain operations. (ir.rezolutebio.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.
Rezolute Financial Performance
Revenues and expenses
Rezolute Earnings Performance
Company profitability
Rezolute News
AllArticlesVideos
Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)
GlobeNewsWire·1 week ago
Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update
GlobeNewsWire·2 months ago
Rezolute to Participate in Upcoming Investor Conferences
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Rezolute stock?
Rezolute (RZLT) has a market cap of $474M as of July 18, 2025.
What is the P/E ratio for Rezolute stock?
The price to earnings (P/E) ratio for Rezolute (RZLT) stock is 0 as of July 18, 2025.
Does Rezolute stock pay dividends?
No, Rezolute (RZLT) stock does not pay dividends to its shareholders as of July 18, 2025.
When is the next Rezolute dividend payment date?
Rezolute (RZLT) stock does not pay dividends to its shareholders.
What is the beta indicator for Rezolute?
Rezolute (RZLT) has a beta rating of 1.04. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.